Immunic (IMUX) Names Erik Lundgren Chief Executive Officer

Immunic Inc. (NASDAQ: IMUX) appointed Erik Lundgren as chief executive officer on May 27, 2026, effective immediately. Lundgren assumes leadership of the clinical-stage biopharmaceutical company focused on oral therapies for autoimmune diseases. Lundgren brings over two decades of biopharmaceutical leadership, most recently serving as chief scientific officer of a multinational pharma company. He succeeds Daniel Vitt, who stepped down after guiding Immunic through pivotal mid-stage trials. The transition occurs as Immunic advances its lead candidate, vidofludimus calcium, in phase 2 studies for multiple sclerosis and inflammatory bowel disease. The company’s stock has declined 34% year-to-date, reflecting broader biotech headwinds and pipeline execution risk.